N6-(1-Naphthylmethyl)adenosine | 21924-65-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N6-(1-Naphthylmethyl)adenosine
• 英文别名: N⁶-<1-naphthylmethyl>adenosine；N⁶-naphthalen-1-ylmethyl-adenosine；N⁶-α-Naphthylmethyladenosin；(2R,3S,4R,5R)-2-Hydroxymethyl-5-{6-[(naphthalen-1-ylmethyl)-amino]-purin-9-yl}-tetrahydro-furan-3,4-diol；(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(naphthalen-1-ylmethylamino)purin-9-yl]oxolane-3,4-diol
• CAS: 21924-65-2
• 化学式: C₂₁H₂₁N₅O₄
• 分子量: 407.429
• InChiKey: FERNSXAXPLJRJD-QTQZEZTPSA-N

物化性质

• 沸点：
  757.5±70.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N6-(1-Naphthylmethyl)adenosine 在 六甲基磷酰三胺 、 氯化亚砜 作用下， 生成
  参考文献：
  名称：

  等位基因特异性蛋白质甲基转移酶抑制剂的设计

  摘要：

  蛋白质精氨酸甲基转移酶催化甲基从 S-腺苷甲硫氨酸 (SAM) 转移到靶蛋白中的精氨酸侧链，调节转录、RNA 加工和受体介导的信号传导。为了专门解决该家族各个成员的功能作用，我们采用了“凹凸洞”的方法，并设计了一系列针对酵母蛋白的 N(6)-取代的 S-腺苷高半胱氨酸 (SAH) 类似物甲基转移酶 RMT1。在 Rmt1 中发现了一个点突变 (E117G)，这使得该酶容易受到 SAH 类似物的选择性抑制。基于质谱的酶分析表明，N(6)-苄基-和 N(6)-萘甲基-SAH 两种化合物可以抑制突变酶，选择性大于 20。当 E117G 突变被引入酿酒酵母染色体时，Npl3p（一种已知的体内 Rmt1 底物）的甲基化可以通过 N(6)-萘基甲基-SAH 在所得等位基因中适度降低。此外，发现 N(6)-苄基-SAM 类似物可作为正交 SAM 辅因子。相对于选择性大于 67 的野生型酶，这种类似物优先

  DOI：

  10.1021/ja011423j
• 作为产物：
  描述：

  1-萘甲基胺 、 6-氯嘌呤核苷 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 N6-(1-Naphthylmethyl)adenosine
  参考文献：
  名称：

  N6-（芳基烷基）腺苷。鉴定N6-（9-芴基甲基）腺苷是腺苷A2受体的高效激动剂。

  摘要：

  合成了几种与N6-苄基腺苷有关的N6-（芳烷基）腺苷，并确定了它们的A1和A2腺苷受体结合亲和力。环状衍生物N6-（1-萘甲基）腺苷产生非常有效的A2激动剂（A1 Ki = 24 nM，A2 Ki = 9.1 nM），而N6-（9-蒽基甲基）腺苷实际上是无活性的（A1 Ki = 9,000 nM ，A 2 Ki = 29,000 nM）。有趣的是，结构相似的N6-（9-芴基甲基）腺苷是迄今为止报道的最有效的A2激动剂，A2结合的Ki为4.9 nM，A1结合的Ki为5.1 nM。N6-9-芴基腺苷和N6- [2-（9-芴基）乙基]腺苷的同系物对任一腺苷受体显示很少或没有活性。这些试剂对离体大鼠心脏的心率和冠状动脉血流的影响分别与其A1和A2结合亲和力平行。

  DOI：

  10.1021/jm00396a044

文献信息

• N6-(Arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor
  作者：B. K. Trivedi、J. A. Bristol、R. F. Bruns、S. J. Haleen、R. P. Steffen

  DOI：10.1021/jm00396a044

  日期：1988.1

  Several N6-(arylalkyl)adenosines related to N6-benzyladenosine were synthesized, and their A1 and A2 adenosine receptor binding affinities were determined. The annulated derivative N6-(1-naphthylmethyl)adenosine resulted in a very potent A2 agonist (A1 Ki = 24 nM, A2 Ki = 9.1 nM), whereas N6-(9-anthracenylmethyl)adenosine was virtually inactive (A1 Ki = 9,000 nM, A2 Ki = 29,000 nM). Interestingly,

  合成了几种与N6-苄基腺苷有关的N6-（芳烷基）腺苷，并确定了它们的A1和A2腺苷受体结合亲和力。环状衍生物N6-（1-萘甲基）腺苷产生非常有效的A2激动剂（A1 Ki = 24 nM，A2 Ki = 9.1 nM），而N6-（9-蒽基甲基）腺苷实际上是无活性的（A1 Ki = 9,000 nM ，A 2 Ki = 29,000 nM）。有趣的是，结构相似的N6-（9-芴基甲基）腺苷是迄今为止报道的最有效的A2激动剂，A2结合的Ki为4.9 nM，A1结合的Ki为5.1 nM。N6-9-芴基腺苷和N6- [2-（9-芴基）乙基]腺苷的同系物对任一腺苷受体显示很少或没有活性。这些试剂对离体大鼠心脏的心率和冠状动脉血流的影响分别与其A1和A2结合亲和力平行。
• N6-substituted adenosines
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0179667A2

  公开（公告）日：1986-04-30

  There is disclosed a compound of the following general formula (I): its diastereomer, or a pharmaceutically acceptable acid addition salt thereof; wherein R1 is of the formula or in which; n is an integer of from one to four; Z is hydrogen, lower alkyl or hydroxy; Y is hydrogen, lower alkyl, or OR where R is hydrogen, lower alkyl or lower alkanoyl; A is a bond or a straight or branched alkylene of from one to four carbon atoms, with the proviso that A cannot be a bond when R1 is of Formula II and n is one; X and X' are each, independently, hydrogen, lower alkyl, lower alkoxy, hydroxy, lower alkanoyl, nitro, trifluoromethyl, halogen, amino, monolower-alkyl or diloweralkylamino, or when taken X and X' together are a methylenedioxy group; R2 is a) hydrogen, b) halogen, c) NR'R" where R' and R" are independently hydrogen, lower alkyl, phenyl, or phenyl substituted by lower alkyl, lower alkoxy, halogen, or trifluoromethyl, d) SR'" where R" is hydrogen, lower alkyl, lower alkanoyl, benzoyl, or phenyl; R'2, R'3 and R'e are each, independently, hydrogen, alkanoyl having two to twelve carbon atoms, inclusive, in a straight or branched alkyl chain, benzoyl, or benzoyl substituted by lower alkyl, lower alkoxy, halogen, or R'2 and R'3 taken together are a five- membered ring having a total of up to twenty carbons; or R'e is, independently, a phosphate, hydrogen, or dihydrogen phosphate, or an alkali metal or ammonium, or dialkali or diammonium salt thereof; with the proviso that overall when R1 is II and X' X', Y, and Z are hydrogen, or lower alkyl then n cannot be two. The novel N6-substituted adenosines have desirable ratio of affinities at A1 or A2 receptors and highly desirable central nervous system and cardiovascular activities, such as analgesic, antipsychotic, sedative, or antihypertensive as well as immunoinflammatory activity.

  本发明公开了一种通式（I）如下的化合物： 其非对映异构体，或其药学上可接受的酸 加成盐； 其中 R1 为式 或 其中 n 是 1 到 4 的整数； Z 是氢、低级烷基或羟基； Y 是氢、低级烷基或 OR，其中 R 是氢、低级烷基或低级烷酰基； A 是键或 1 至 4 个碳原子的直链或支链亚烷基，但当 R1 为式 II 且 n 为 1 时，A 不能为键； X和X'各自独立地为氢、低级烷基、低级烷氧基、羟基、低级烷酰基、硝基、三氟甲基、卤素、氨基、单低级烷基或稀低烷基氨基，或当X和X'合在一起时为亚甲基二氧基； R2 是 a) 氢，b) 卤素，c) NR'R"，其中 R' 和 R "独立地是氢、低级烷基、苯基或被低级烷基、低级烷氧基、卤素或三氟甲基取代的苯基，d) SR'"，其中 R" 是氢、低级烷基、低级烷酰基、苯甲酰基或苯基； R'2、R'3 和 R'e 各自独立地是氢、在直链或支链烷基中具有 2 至 12 个碳原子的烷酰基、苯甲酰基或被低级烷基、低级烷氧基、卤素取代的苯甲酰基，或 R'2 和 R'3 合在一起是一个总碳数不超过 20 个的五元环；或 R'e 独立地是磷酸、氢或磷酸二氢、或碱金属或铵、或二碱或二铵盐；但总体上，当 R1 是 II 且 X' X'、Y 和 Z 是氢、或低级烷基时，则 n 不能为 2。 新型 N6 取代腺苷在 A1 或 A2 受体上具有理想的亲和力比率，并具有非常理想的中枢神经系统和心血管活性，如镇痛、抗精神病、镇静或抗高血压以及免疫炎症活性。
• Adenosine Analogues as Inhibitors of <i>Trypanosoma </i><i>b</i><i>rucei </i>Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine
  作者：Jerome C. Bressi、Jungwoo Choe、Melinda T. Hough、Frederick S. Buckner、Wesley C. Van Voorhis、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm000287a

  日期：2000.11.1

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.
• Selective Tight Binding Inhibitors of Trypanosomal Glyceraldehyde-3-phosphate Dehydrogenase via Structure-Based Drug Design
  作者：Alex M. Aronov、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm9802620

  日期：1998.11.1

  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from the sleeping sickness parasite Trypanosoma brucei is a rational target for anti-trypanosomatid drug design because glycolysis provides virtually all of the energy for the bloodstream form of this parasite. Glycolysis is also an important source of energy for other pathogenic parasites including Trypanosoma cruzi and Leishmania mexicana. The current study is a continuation of our efforts to use the X-ray structures of T. brucei and L. mexicana GAPDHs containing bound NAD(+) to design adenosine analogues that bind tightly to the enzyme pocket that accommodates the adenosyl moiety of NAD(+). The goal was to improve the affinity, selectivity, and solubility of previously reported 2'-deoxy-2'-(3-methoxybenzamido)adenosine (1). It was found that introduction of hydroxyl functions on the benzamido ring increases solubility without significantly affecting enzyme inhibition. Modifications at the previously unexploited N-6-position of the purine not only lead to a substantial increase in inhibitor potency but are also compatible with the 2'-benzamido moiety of the sugar. For N-6-substituted adenosines, two successive rounds of modeling and screening provided a 330-fold gain in affinity versus that of adenosine. The combination of N-6- and 2'-substitutions produced significantly improved inhibitors. N-6-Benzyl (9a) and N-6-2-methylbenzyl (9b) derivatives of 1 display IC50 values against L. mexicana GAPDH of 16 and 4 mu M, respectively (3100- and 12500-fold more potent than adenosine). The adenosine analogues did not inhibit human GAPDH. These studies underscore the usefulness of structure-based drug design for generating potent and species-selective enzyme inhibitors of medicinal importance starting from a weakly binding lead compound.
• Anti-Malarial activity of N6-Substituted adenosine derivatives. Part I
  作者：Abolfasl Golisade、Jochen Wiesner、Claudia Herforth、Hassan Jomaa、Andreas Link

  DOI：10.1016/s0968-0896(01)00331-5

  日期：2002.3

  The synthesis and biological evaluation of novel N(6)-substituted adenosine derivatives is reported. The first series of compounds was obtained using an established procedure for the nucleophilic substitution of a 1-(6-chloro-purin-9-yl)-beta-D-1-deoxy-ribofuranose with various amines. In addition, attachment of two different amino-functionalised spacer arms at the N(6)-position of adenosine enabled

  报道了新型N（6）-取代的腺苷衍生物的合成和生物学评估。使用用于用各种胺亲核取代1-（6-氯嘌呤-9-基）-β-D-1-脱氧核糖呋喃糖的既定程序，获得第一系列化合物。此外，在腺苷的N（6）位置的两个不同的氨基官能化间隔臂的连接能够通过创新的聚合物辅助协议进行衍生化。因此，我们能够制备出三个系列的取代衍生物，它们在细胞培养实验中显示出与多抗性恶性疟原虫菌株Dd2相比具有活性。